These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 19910427

  • 1. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.
    J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
    [Abstract] [Full Text] [Related]

  • 2. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD.
    J Nucl Med; 2006 Jul; 47(7):1144-52. PubMed ID: 16818949
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo metabolism of Lu-AMBA, a GRP-receptor binding compound, and the synthesis and characterization of its metabolites.
    Linder KE, Metcalfe E, Arunachalam T, Chen J, Eaton SM, Feng W, Fan H, Raju N, Cagnolini A, Lantry LE, Nunn AD, Swenson RE.
    Bioconjug Chem; 2009 Jun; 20(6):1171-8. PubMed ID: 19480415
    [Abstract] [Full Text] [Related]

  • 4. Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
    Liu IH, Chang CH, Ho CL, Chiu SP, Lee WC, Chang TJ, Chen LC, Wu YH, Chuang CH, Fu YK, Lee TW.
    Anticancer Res; 2010 Oct; 30(10):4039-48. PubMed ID: 21036718
    [Abstract] [Full Text] [Related]

  • 5. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.
    Thomas R, Chen J, Roudier MM, Vessella RL, Lantry LE, Nunn AD.
    Clin Exp Metastasis; 2009 Oct; 26(2):105-19. PubMed ID: 18975117
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
    Dalm SU, Martens JW, Sieuwerts AM, van Deurzen CH, Koelewijn SJ, de Blois E, Maina T, Nock BA, Brunel L, Fehrentz JA, Martinez J, de Jong M, Melis M.
    J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
    [Abstract] [Full Text] [Related]

  • 7. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
    [Abstract] [Full Text] [Related]

  • 10. Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA.
    Cagnolini A, Chen J, Ramos K, Skedzielewski TM, Lantry LE, Nunn AD, Swenson RE, Linder KE.
    Appl Radiat Isot; 2010 Dec; 68(12):2285-92. PubMed ID: 20638858
    [Abstract] [Full Text] [Related]

  • 11. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [Abstract] [Full Text] [Related]

  • 12. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, Weber WA, Mansi R.
    J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
    [Abstract] [Full Text] [Related]

  • 13. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR.
    Cancer Res; 2011 Feb 01; 71(3):1009-18. PubMed ID: 21245097
    [Abstract] [Full Text] [Related]

  • 14. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.
    J Nucl Med; 2004 Aug 01; 45(8):1390-7. PubMed ID: 15299066
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.
    Nucl Med Biol; 2009 Aug 01; 36(6):591-603. PubMed ID: 19647165
    [Abstract] [Full Text] [Related]

  • 17. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ.
    Nucl Med Biol; 2003 Feb 01; 30(2):101-9. PubMed ID: 12623108
    [Abstract] [Full Text] [Related]

  • 18. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan 01; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 19. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M.
    Int J Cancer; 2010 Jun 15; 126(12):2826-34. PubMed ID: 19876914
    [Abstract] [Full Text] [Related]

  • 20. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
    Marsouvanidis PJ, Melis M, de Blois E, Breeman WA, Krenning EP, Maina T, Nock BA, de Jong M.
    Cancer Biother Radiopharm; 2014 Nov 15; 29(9):359-67. PubMed ID: 25286347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.